Veracyte company info

What does Veracyte do?
Veracyte (NASDAQ:VCYT) is a diagnostic company that focuses on delivering genomic solutions to improve patient outcomes and reduce healthcare costs. It specializes in developing tests for the early detection of cancer and other diseases, providing physicians with actionable insights for patient care. Veracyte's portfolio includes tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis, among others. The company is committed to expanding its product range and enhancing its global presence through strategic partnerships and research advancements. Its operations span from the development and commercialization of its tests to collaborating with biopharmaceutical companies for companion diagnostic development. Veracyte aims to transform the diagnostic landscape by offering precise and minimally invasive tests, thereby enabling better disease management and treatment decisions for patients around the world.
Veracyte company media
Company Snapshot

Is Veracyte a public or private company?

key
Ownership
Public

How many people does Veracyte employ?

people
Employees
566

What sector is Veracyte in?

pie chart
Sector
Health Care

Where is the head office for Veracyte?

location pin
Head Office
South San Francisco, United States

What year was Veracyte founded?

founded flag
Year Founded
2006
What does Veracyte specialise in?
/Genomic Diagnostics /Advanced Biotechnology /Precision Medicine /Proprietary Tests /Machine Learning /Healthcare Solutions

What are the products and/or services of Veracyte?

Overview of Veracyte offerings
Afirma Genomic Sequencing Classifier helps in identifying benign thyroid nodules to avoid unnecessary surgeries.
Envisia Genomic Classifier aids in diagnosing interstitial lung diseases, including idiopathic pulmonary fibrosis.
Percepta Genomic Sequencing Classifier is used for lung cancer risk assessment in patients with inconclusive lung nodules.
Prosigna Breast Cancer Prognostic Gene Signature Assay provides information on the risk of recurrence for breast cancer patients.
Decipher Prostate Genomic Classifier offers a risk assessment for prostate cancer progression and metastasis.
LymphMark, a lymphoma subtyping test, helps in the diagnosis and treatment planning for B-cell lymphoma.

Who is in the executive team of Veracyte?

Veracyte leadership team
  • Mr. Marc A. Stapley
    Mr. Marc A. Stapley
    CEO & Director
  • Ms. Rebecca  Chambers
    Ms. Rebecca Chambers
    Executive VP & CFO
  • Ms. Annie  McGuire
    Ms. Annie McGuire
    Executive VP, General Counsel & Chief People Officer
  • Mr. Jonathan  Wygant
    Mr. Jonathan Wygant
    VP & Chief Accounting Officer
  • Mr. Steven  French
    Mr. Steven French
    Senior VP & Chief Information Officer
  • Dr. Phillip G. Febbo M.D.
    Dr. Phillip G. Febbo M.D.
    Chief Scientific & Medical Officer
  • Ms. Karen  Possemato
    Ms. Karen Possemato
    Senior Vice President of Corporate Marketing, Communications & Commercial Operations
  • Mr. Robert  Brainin
    Mr. Robert Brainin
    Executive VP & Chief Business Officer